Ironwood Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Okay. Hey, everybody. I'm Marty Auster. I'm the lead SMID cap biotech analyst at Crédit Suisse. You are watching the 29th Annual Crédit Suisse Healthcare Conference. And I've got Ironwood Pharma with me today. I've got CEO, Mark Mallon, and his team.
Mark, maybe before we jump into the Q&A, if you could kind of frame Ironwood for us a little bit, catch us up and kind of just maybe give us an overview of the IBS-C market and LINZESS and sort of kind of the Ironwood vision. And we'll jump off there.
Sure. Thanks. First, let me say, Marty, thanks for this opportunity. And thanks to you and Crédit Suisse, and welcome, everybody. We appreciate the opportunity to update you on Ironwood.
So as I think many people know, Ironwood is a GI-focused health care company, aimed to be a leader in the GI space. We've been very successful in including in 2020 with bringing an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
